智通财经网·2025-09-02 11:40Core Viewpoint - Junshi Biosciences (688180.SH) announced that its subsidiary, Shanghai Juntao Biopharmaceutical Technology Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of JT118 injection, aimed at preventing monkeypox virus infection [1] Group 1: Company Developments - The clinical trial application for JT118 injection has been approved, allowing the company to conduct trials for its use against monkeypox virus [1] - JT118 is a "two-in-one" recombinant protein vaccine composed of monkeypox virus antigens A35 (extracellular membrane virus antigen) and M1 (intracellular mature virus antigen) [1] - The vaccine retains the structural epitopes of both natural antigens A35 and M1 while significantly increasing molecular weight through multi-antigen fusion, enhancing immune response [1] Group 2: Industry Context - Monkeypox is a zoonotic viral disease caused by the monkeypox virus, classified under the Orthopoxvirus genus of the Poxviridae family [1] - The monkeypox virus replicates in two different forms: extracellular membrane virus and intracellular mature virus, both of which are infectious [1]